[Treatment of metastatic melanoma: are we entering the era of targeted treatment?].

Abstract

The treatment of metastatic melanoma has progressed greatly during the last two years. Nowadays melanomas can be divided into molecular subgroups, this being therapeutically relevant. Around 60% of melanomas show a BRAF mutation and can be treated with selected tyrokinase inhibitors. In addition a CTLA-4-antibody was developed which shuts off the natural immune breaking system resulting in a continuous anti-tumor reaction. Angiogenesis inhibitors have shown there importance in different phase II trials. We hope that this represents only the first step of an individualized treatment for metastatic melanoma.

DOI: 10.1024/1661-8157/a001030

Cite this paper

@article{Moos2012TreatmentOM, title={[Treatment of metastatic melanoma: are we entering the era of targeted treatment?].}, author={Roger von Moos and Richard Cathomas and Melanie D Mark and Fabienne Hitz}, journal={Praxis}, year={2012}, volume={101 22}, pages={1423-9} }